Condition: Prostate Cancer · Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd
A Phase I/IIa clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of INR102 injection in patients with prostate cancer.
This description comes directly from the study's public registry record.
Dong Yuan · +86-18611999529 · yuandong@ynby.cn
Always discuss trial participation with your own doctor first.
| Affiliated Hospital of Jiangnan University | Wuxi, Jiangsu, China | Not Yet Recruiting |
| Tianjin Cancer Hospital Airport Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06970119